Graef, Claus Moritz, Goedel, Philipp, Falderbaum, Philipp, Balke-Want, Hyatt, Simon, Florian ORCID: 0000-0002-2700-3717, Sieg, Noelle, Naendrup, Jan-Hendrik, Neumann, Marie Anne-Catherine ORCID: 0000-0002-2396-6110, Gillessen, Sarah, Broeckelmann, Paul J., Eichenauer, Dennis A., Borchmann, Peter, von Tresckow, Bastian and Heger, Jan-Michel ORCID: 0000-0001-9463-8504 (2022). Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma. Eur. J. Haematol., 108 (5). S. 403 - 413. HOBOKEN: WILEY. ISSN 1600-0609

Full text not available from this repository.

Abstract

Background Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) are aggressive B-cell non-Hodgkin lymphomas (B-NHL) with a generally favorable prognosis after immunochemotherapy. The outcome of BL is superior to DLBCL. In 2016, a distinct group of lymphomas displaying characteristics of both BL and DLBCL (high grade B-cell lymphoma, HGBL) was introduced into the WHO classification. Histopathological discrimination of BL, DLBCL, and HGBL may be challenging. Data on the frequency of histopathological difficulties resulting in revision of the final diagnosis of BL/DLBCL/HGBL and its impact on the prognosis are limited. Methods We assessed histopathological features and clinical outcomes of 66 patients with suspected diagnosis of BL at the reporting institution between 2010 and 2020. Results The median age was 51 years (range 19-82) and final histopathological diagnosis revealed BL (n = 40), DLBCL (n = 12), or HGBL (n = 14). Patients with DLBCL and HGBL were either treated with DLBCL-directed (83.3% and 35.7%) or BL-directed (16.7% and 64.3%) protocols. Patients in whom diagnosis was revised from DLBCL to BL after initiation of DLBCL-directed treatment had a significantly inferior progression-free survival (PFS) than patients initially diagnosed with BL (p = 0.045), thus resembling rather the prognosis of DLBCL/HGBL. There was no difference between patients with DLBCL and HGBL, respectively, regarding PFS and OS (p = 0.38 and p = 0.27). Conclusion These results suggest that timely and precise histopathological diagnosis as well as reference histopathological review of the underlying lymphoma is critical to determine up-front treatment strategies. Consequently, selection of more aggressive treatment protocols in case of difficulties with discrimination between DLBCL/HGBL/BL may be a reasonable approach.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Graef, Claus MoritzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goedel, PhilippUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Falderbaum, PhilippUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Balke-Want, HyattUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Simon, FlorianUNSPECIFIEDorcid.org/0000-0002-2700-3717UNSPECIFIED
Sieg, NoelleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Naendrup, Jan-HendrikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Neumann, Marie Anne-CatherineUNSPECIFIEDorcid.org/0000-0002-2396-6110UNSPECIFIED
Gillessen, SarahUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Broeckelmann, Paul J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eichenauer, Dennis A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borchmann, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Tresckow, BastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heger, Jan-MichelUNSPECIFIEDorcid.org/0000-0001-9463-8504UNSPECIFIED
URN: urn:nbn:de:hbz:38-681439
DOI: 10.1111/ejh.13747
Journal or Publication Title: Eur. J. Haematol.
Volume: 108
Number: 5
Page Range: S. 403 - 413
Date: 2022
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1600-0609
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
BCL6 REARRANGEMENTS; CHOP CHEMOTHERAPY; MYC GENE; RITUXIMAB; CLASSIFICATION; PROGNOSIS; MULTICENTER; SURVIVAL; THERAPYMultiple languages
HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/68143

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item